1. Home
  2. INLX vs SAVA Comparison

INLX vs SAVA Comparison

Compare INLX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INLX
  • SAVA
  • Stock Information
  • Founded
  • INLX 1996
  • SAVA 1998
  • Country
  • INLX United States
  • SAVA United States
  • Employees
  • INLX N/A
  • SAVA N/A
  • Industry
  • INLX EDP Services
  • SAVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • INLX Technology
  • SAVA Health Care
  • Exchange
  • INLX Nasdaq
  • SAVA Nasdaq
  • Market Cap
  • INLX 62.4M
  • SAVA 70.5M
  • IPO Year
  • INLX N/A
  • SAVA N/A
  • Fundamental
  • Price
  • INLX $12.54
  • SAVA $2.01
  • Analyst Decision
  • INLX
  • SAVA Buy
  • Analyst Count
  • INLX 0
  • SAVA 3
  • Target Price
  • INLX N/A
  • SAVA $54.50
  • AVG Volume (30 Days)
  • INLX 13.1K
  • SAVA 857.6K
  • Earning Date
  • INLX 08-12-2025
  • SAVA 08-07-2025
  • Dividend Yield
  • INLX N/A
  • SAVA N/A
  • EPS Growth
  • INLX N/A
  • SAVA N/A
  • EPS
  • INLX N/A
  • SAVA N/A
  • Revenue
  • INLX $17,758,634.00
  • SAVA N/A
  • Revenue This Year
  • INLX $7.58
  • SAVA N/A
  • Revenue Next Year
  • INLX N/A
  • SAVA N/A
  • P/E Ratio
  • INLX N/A
  • SAVA N/A
  • Revenue Growth
  • INLX 3.21
  • SAVA N/A
  • 52 Week Low
  • INLX $5.91
  • SAVA $1.15
  • 52 Week High
  • INLX $16.50
  • SAVA $42.20
  • Technical
  • Relative Strength Index (RSI)
  • INLX 53.15
  • SAVA 51.81
  • Support Level
  • INLX $10.40
  • SAVA $2.01
  • Resistance Level
  • INLX $11.95
  • SAVA $2.17
  • Average True Range (ATR)
  • INLX 0.72
  • SAVA 0.10
  • MACD
  • INLX 0.00
  • SAVA -0.02
  • Stochastic Oscillator
  • INLX 70.86
  • SAVA 17.31

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About SAVA Cassava Sciences Inc.

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Share on Social Networks: